Macroeconomic challenges that have hindered biotech IPO activity are subsiding and capital markets are expected to improve later in 2026, especially for early-stage biotech companies. Increased M&A activity by Big Pharma, anticipated interest rate cuts, and a backlog of companies with late-stage assets suggest an uptick in IPO activity in late 2026 and into 2027. Navigating strategic transactions like an IPO is complex, and preparation is critical, particularly as it relates to public company operations. CEOs and companies who can prioritize their strategic timeline and begin to build muscle memory around operating as a public company will find themselves in the best position to be successful and create organizational value. Preparation is key to capitalizing on potentially fleeting market windows with confidence. This panel will dive into lessons learned from past IPOs and how early-stage biotech’s can avoid common pitfalls.